Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Bemcentinib

Catalog No: tcsc1046

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1037624-75-1

Formula:
$C_{30}H_{34}N_8$

Pathway:
Protein Tyrosine Kinase/RTK

Target:
TAM Receptor

Purity / Grade:
>98%

Solubility:
DMSO : 10.25 mg/mL (20.23 mM; Need ultrasonic and warming)

Alternative Names:
R428;BGB324

Observed Molecular Weight:
506.64

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Bemcentinib (R428) is a potent and selective inhibitor of **Axl** with an **IC_{50}** of 14 nM.

IC50 & Target: IC50: 14 nM (Axl kinase)

In Vitro: Bemcentinib (R428) (2μM) significantly interferes with mechanisms of migration and invasion of Axlpos melanoma cells at levels comparable to Axl knockdown[1]. Bemcentinib (R428) synergizes with cisplatin to enhance suppression of liver micrometastasis [2]. Bemcentinib (R428) (50 nM-1μM) causes a concentration-dependent inhibition of preadipocyte differentiation into mature adipocytes, as evidenced by reduced lipid uptake[3].

In Vivo: Bemcentinib (R428) (125 mg/kg, p.o.) significantly blocks MDA-MB-231-luc-D3H2LN metastases development in two independent mouse models of breast cancer dissemination, suppresses both tumor angiogenesis and vascular endothelial growth factor (VEGF)-induced corneal neovascularization in vivo[2]. Bemcentinib (R428) (75 mg/kg/day, 25 mg/kg twice daily, p.o.) makes mice keep on a high-fat diet resulted in significantly reduced weight gain and subcutaneous and gonadal fat mass[3].